Overview

A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

The main objective of this study is to demonstrate the efficacy and safety of multiple-dose application of three different oral doses of CG5503 IR (tapentadol immediate release) compared to placebo in women undergoing abdominal hysterectomy.

Phase:

Phase 3

Details

Lead Sponsor:

Grünenthal GmbH

Collaborator:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Treatments:

Morphine
Tapentadol